Congestive Heart Failure in Dogs: Welfare Management in End-Stage Disease

How congestive heart failure affects dog welfare through breathlessness, fatigue, and fluid accumulation, and how palliative management can maintain quality of life.

Key Facts

Congestive heart failure (CHF) in dogs occurs when the heart cannot maintain adequate cardiac output, causing fluid accumulation in the lungs (left-sided) or abdomen (right-sided)
Myxomatous mitral valve disease (MMVD) is the most common cause in small breeds; dilated cardiomyopathy (DCM) is most common in large breeds
Cavalier King Charles Spaniels, Dachshunds, and other small breeds have high MMVD prevalence, with disease developing earlier in affected breed lines
Breathlessness from pulmonary oedema is one of the most distressing symptoms a dog can experience and requires urgent emergency management
Treatment with diuretics, ACE inhibitors, and pimobendan extends comfortable life significantly — dogs diagnosed in early CHF may live 1-3 additional years with good management
The QUEST trial demonstrated that pimobendan started in preclinical MMVD delays onset of CHF, opening a welfare-positive intervention window
Quality of life assessment tools help owners and vets recognise when medical management is no longer controlling suffering

Welfare Considerations

Heart failure in dogs causes welfare compromise primarily through breathlessness — one of the most distressing experiences for any mammal. Dogs in acute decompensated heart failure show profound respiratory distress, anxiety, and inability to rest comfortably. Even in stable, medically managed CHF, exercise intolerance and fatigue limit daily activities and quality of life. The goal of medical management is to extend the period of good quality life by controlling fluid accumulation and supporting cardiac function. This requires owner engagement with home monitoring — including resting respiratory rate as a key early warning sign of decompensation. End-of-life planning for CHF dogs benefits from proactive quality of life conversations, ensuring that euthanasia occurs before severe breathlessness rather than reactively during an acute crisis.

What You Can Do

Learn to count your dog's resting respiratory rate (RRR) if diagnosed with heart disease — rates above 30 breaths/minute at rest indicate concern
Start Pimobendan early if recommended for preclinical MMVD — this delays heart failure onset and preserves quality of life
Ensure prompt veterinary assessment for any sudden increase in breathing rate or effort in heart disease dogs
Have an end-of-life quality of life conversation with your vet before crisis — planned euthanasia prevents a distressing acute episode
Support breeding programmes that test for MMVD and select against early-onset disease in predisposed breeds